GetTopicDetailResponse(id=ef90153940f, topicName=RET融合, introduction=RET融合, content=null, image=null, comments=1, allHits=1247, url=https://h5.medsci.cn/topic?id=15394, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=64393, tagList=[TagDto(tagId=64393, tagName=RET融合)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2274919, encodeId=e64a22e49197b, content=<a href='/topic/show?id=bec66989e9a' target=_blank style='color:#2F92EE;'>#甲狀腺癌#</a> <a href='/topic/show?id=ef90153940f' target=_blank style='color:#2F92EE;'>#RET融合#</a>, objectTitle=BRAF突變?nèi)轭^狀甲狀腺癌預(yù)后更佳？大樣本揭示：互斥性RET融合才是侵襲復(fù)發(fā)主因, objectType=article, longId=888524, objectId=94bc88852459, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=94bc88852459, replyNumber=0, likeNumber=20, createdTime=2025-07-26, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=94bc88852459, moduleTitle=BRAF突變?nèi)轭^狀甲狀腺癌預(yù)后更佳？大樣本揭示：互斥性RET融合才是侵襲復(fù)發(fā)主因, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=94bc88852459)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2145412, encodeId=6ddd2145412ad, content=<a href='/topic/show?id=68f8106369fc' target=_blank style='color:#2F92EE;'>#普拉替尼#</a>一線治療<a href='/topic/show?id=ef90153940f' target=_blank style='color:#2F92EE;'>#RET融合#</a>陽性<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細胞肺癌#</a>的新適應(yīng)癥在中國獲批, objectTitle=普拉替尼一線治療RET融合陽性非小細胞肺癌的新適應(yīng)癥在中國獲批, objectType=article, longId=779170, objectId=c72ae7917024, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024236648_4754896.jpeg, objectUrl=/article/show_article.do?id=c72ae7917024, replyNumber=0, likeNumber=151, createdTime=2023-06-29, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=c72ae7917024, moduleTitle=普拉替尼一線治療RET融合陽性非小細胞肺癌的新適應(yīng)癥在中國獲批, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c72ae7917024)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
